{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:39:17Z","timestamp":1788593957299,"version":"build-2803163510"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BMBF"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on overall survival. However, the data underpinning these guidelines are mainly from trials of the 1980s\/1990s and have not been updated to reflect the significant advancements in diagnostic and therapeutic options that have emerged over the past 40 years. In this trial, the aim is to test whether a liquid biopsy-based detection of (oligo-) metastatic disease at an early pre-symptomatic stage followed by timely treatment can impact overall survival compared to current standard aftercare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this partially double-blinded superiority study, intensified liquid biopsy-guided surveillance will be assessed versus standard surveillance in medium-to-high-risk early breast cancer patients. Intensive surveillance comprises 3-monthly tests of circulating free tumor DNA (ctDNA), circulating tumor cells (CTC) and serum tumor markers CEA, CA 27.29 and CA125. Upon positivity of biomarker and\/or symptoms, staging examinations are initiated. In total, 3500 patients will be randomized in a 1:1 ratio after completion of primary antineoplastic therapy. Co-primary endpoints are overall survival (OS) and the overall lead time effect. The trial will be accompanied by an extensive translational research program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>A risk-based aftercare and regular screening for asymptomatic metastatic disease with molecular markers in the absence of any radiological findings can potentially revolutionize current follow-up care of breast cancer survivors and enable potential treatment even before patients suffer from symptomatic, incurable disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0331203","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:31:47Z","timestamp":1757439107000},"page":"e0331203","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors"],"prefix":"10.1371","volume":"20","author":[{"given":"Tatjana","family":"Braun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Huesmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2831-1401","authenticated-orcid":true,"given":"Kerstin","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4773-8067","authenticated-orcid":true,"given":"Thomas W. P.","family":"Friedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hartkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forca","family":"Mehmeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Mergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Sch\u00e4ffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heublein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wiesm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Rack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9481-830X","authenticated-orcid":true,"given":"Angelina","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"pone.0331203.ref001","unstructured":"https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/20-breast-fact-sheet.pdf Accessed 2025 January 4."},{"issue":"7","key":"pone.0331203.ref002","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2012.45.9859","article-title":"Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update","volume":"31","author":"JL Khatcheressian","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0331203.ref003","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"S Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"20","key":"pone.0331203.ref004","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1001\/jama.1994.03510440053032","article-title":"Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. national research council project on breast cancer follow-up","volume":"271","author":"M Rosselli Del Turco","year":"1994","journal-title":"JAMA"},{"issue":"20","key":"pone.0331203.ref005","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jama.1994.03510440047031","article-title":"Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators","volume":"271","year":"1994","journal-title":"JAMA"},{"issue":"1","key":"pone.0331203.ref006","article-title":"Follow-up strategies for women treated for early breast cancer","author":"MP Rojas","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"pone.0331203.ref007","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0331203.ref008","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer","volume":"390","author":"D Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0331203.ref009","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-Year efficacy outcomes","volume":"42","author":"P Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"18","key":"pone.0331203.ref010","doi-asserted-by":"crossref","first-page":"13726","DOI":"10.3390\/ijms241813726","article-title":"Antibody-drug conjugates in breast cancer: current status and future directions","volume":"24","author":"C Mark","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"10","key":"pone.0331203.ref011","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1158\/1078-0432.CCR-15-1603","article-title":"Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer","volume":"22","author":"WJ Janni","year":"2016","journal-title":"Clin Cancer Res"},{"key":"pone.0331203.ref012","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1200\/jco.2010.28.15_suppl.1003","article-title":"Use of circulating tumor cells (CTC) in peripheral blood of breast cancer patients before and after adjuvant chemotherapy to predict risk for relapse: The SUCCESS trial","volume":"28","author":"BK Rack","year":"2010","journal-title":"JCO"},{"issue":"4","key":"pone.0331203.ref013","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/djy152","article-title":"Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis","volume":"111","author":"E Trapp","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"pone.0331203.ref014","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3390\/cancers14071721","article-title":"MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients","volume":"14","author":"H Huebner","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"pone.0331203.ref015","doi-asserted-by":"crossref","first-page":"102390","DOI":"10.1016\/j.esmoop.2024.102390","article-title":"Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis","volume":"9","author":"G Nader-Marta","year":"2024","journal-title":"ESMO Open"},{"issue":"22","key":"pone.0331203.ref016","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1200\/JCO.22.00908","article-title":"Circulating tumor DNA and late recurrence in high-risk Hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer","volume":"40","author":"M Lipsyc-Sharf","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"pone.0331203.ref017","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer","volume":"5","author":"I Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"issue":"14","key":"pone.0331203.ref018","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA Antedates Breast Cancer Metastatic Recurrence","volume":"25","author":"RC Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"pone.0331203.ref019","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10549-017-4513-0","article-title":"Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing","volume":"167","author":"DC Lin","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"pone.0331203.ref020","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/annonc\/mds604","article-title":"Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer","volume":"24","author":"JS Lee","year":"2013","journal-title":"Ann Oncol"},{"issue":"9","key":"pone.0331203.ref021","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.21873\/anticanres.11034","article-title":"Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial","volume":"36","author":"P Hepp","year":"2016","journal-title":"Anticancer Res"},{"issue":"1","key":"pone.0331203.ref022","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13058-020-01348-w","article-title":"Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial","volume":"22","author":"A de Gregorio","year":"2020","journal-title":"Breast Cancer Res"},{"key":"pone.0331203.ref023","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cca.2015.06.022","article-title":"Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients","volume":"448","author":"P Stieber","year":"2015","journal-title":"Clin Chim Acta"},{"issue":"5","key":"pone.0331203.ref024","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/bjc.2015.8","article-title":"Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase","volume":"112","author":"D Di Gioia","year":"2015","journal-title":"Br J Cancer"},{"key":"pone.0331203.ref025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2016.07.014","article-title":"Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3","volume":"461","author":"D Di Gioia","year":"2016","journal-title":"Clin Chim Acta"},{"issue":"1","key":"pone.0331203.ref026","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"RL Siegel","year":"2020","journal-title":"CA: A Cancer J Clinicians"},{"issue":"7","key":"pone.0331203.ref027","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/cam4.2830","article-title":"Impact of delayed treatment in women diagnosed with breast cancer: A population-based study","volume":"9","author":"PJ Ho","year":"2020","journal-title":"Cancer Med"},{"key":"pone.0331203.ref028","first-page":"3511","article-title":"Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients","volume":"19","author":"S Lauro","year":"1999","journal-title":"Anticancer Res"},{"issue":"32","key":"pone.0331203.ref029","doi-asserted-by":"crossref","first-page":"22523","DOI":"10.18632\/oncotarget.25077","article-title":"Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA","volume":"9","author":"M Zaleski","year":"2018","journal-title":"Oncotarget"},{"issue":"33","key":"pone.0331203.ref030","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"L Harris","year":"2007","journal-title":"J Clin Oncol"},{"key":"pone.0331203.ref031","year":"2021"},{"issue":"1","key":"pone.0331203.ref032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1245\/s10434-024-16287-5","article-title":"Surveillance-associated anxiety after curative-intent cancer surgery: a systematic review","volume":"32","author":"R Khatri","year":"2025","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"pone.0331203.ref033","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMra072149","article-title":"Computed tomography--an increasing source of radiation exposure","volume":"357","author":"DJ Brenner","year":"2007","journal-title":"N Engl J Med"},{"key":"pone.0331203.ref034","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.2022.40.16_suppl.1007","article-title":"NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557)","volume":"40","author":"SJ Chmura","year":"2022","journal-title":"JCO"},{"issue":"10185","key":"pone.0331203.ref035","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"DA Palma","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"pone.0331203.ref036","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"DA Palma","year":"2020","journal-title":"J Clin Oncol"},{"issue":"24","key":"pone.0331203.ref037","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding Adjuvant therapy in stage II colon cancer","volume":"386","author":"J Tie","year":"2022","journal-title":"N Engl J Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331203","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:31:54Z","timestamp":1757439114000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331203"}},"subtitle":[],"editor":[{"given":"Elingarami","family":"Sauli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0331203","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]}}}